Labcorp Holdings will report its second-quarter results by the end of this month, and analysts are anticipating a ...

Coverage and future reimbursement (effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered ...

Detailed price information for Laboratory Corp of America (LH-N) from The Globe and Mail including charting and trades.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the ...

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on ...

A healthcare company is preparing to pay $35,000,000 to settle a class action lawsuit over a cybersecurity incident that ...

The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

More Bonds of Labcorp Holdings Inc. Moody’s Daily Credit Risk Score About the Labcorp Holdings Inc.-Bond (US50540RAU68) The Labcorp Holdings Inc.-Bond has a maturity date of 9/1/2027 and offers a ...

Shares of Labcorp Holdings Inc. LH rallied 1.39% to $283.88 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.22% to 7,483 ...

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

Last week, readers were most interested in a story about an allegation that Invitae illegally shared patients' genetic data.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal ...